(BUSINESS WIRE) --
According to news on June 29 from Middle East News Agency, Favipiravir,
the popular drug used for treating COVID-19 has shown excellent results
in clinical tests. AP, Fox and Deutsche Presse-Agentur have also
reported the important role of Favipiravir in the successful fight
against the virus in China.
Favipiravir
was originally developed by Toyama Chemical Co., Ltd. In 2016, the
patent of Favipiravir was exclusively franchised to Zhejiang Hisun
Pharmaceutical Co., Ltd. (Hisun), which cooperated with CMAM to develop
Favipiravir tablets. The finished drug was approved rapidly in the
Chinese market in February 2020. Since the outbreak of COVID-19,
Favipiravir has been strongly recommended by the Chinese and Japanese
governments and used in clinical tests for treating COVID-19 since
February. Now it has been included in the diagnosis and treatment
guidelines of Saudi Arabia, UAE and many other countries, and has been
approved for indications of the disease in Russia and India. Stanford
Medicine in the US (https://www.clinicaltrialsarena.com/news/stanford-favipiravir-covid19-trial/) and the Italian Medicines Agency (AIFA) (https://europost.eu/en/a/view/italy-starts-testing-antiviral-drug-avigan-against-covid-19-27664) have approved tests on efficacy of Favipiravir on the novel coronavirus as well.
The
ongoing global multicenter clinical trials of Favipiravir in treating
COVID-19 have shown remarkable efficacy and safety. Trial findings of
Hisun’s Favipiravir versus other drugs used in treating the virus from
the Third People’s Hospital of Shenzhen showed that those who took
Favipiravir turned negative in viral nucleic acid tests in a shorter
period of time (4 days), compared to the control group (11 days); higher
improvement rate in chest imaging of 91.43% versus 62.22%, as well as
higher level of safety. Inspiring results had also been seen in the
early clinical trials of Favipiravir in Russia and Bangladesh: 60% of
the Russian patients (40 in total) and 48% (50 in total) of Bangladeshi
patients turned negative after 4-5 days, all without obvious adverse
reactions or side effects.
The
high quality Hisun’s Favipiravir in adequate supply has been through
all channels across China. Keeping a close eye on the global fight
against COVID-19, Hisun has sent Favipiravir to support over 20
countries since this March. Currently, it has built long-term
partnerships with seven Middle East countries in continued support for
their battle against the disease.
Contacts
Ms Li Huimin
Email: hisun-haisheng@hisunpharm.com
